Comparative Pharmacology
Head-to-head clinical analysis: BENDECTIN versus DIMENHYDRINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDECTIN versus DIMENHYDRINATE.
BENDECTIN vs DIMENHYDRINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of doxylamine (antihistamine) and pyridoxine (vitamin B6). Doxylamine blocks histamine H1 receptors, reducing nausea and vomiting. Pyridoxine acts as a cofactor in neurotransmitter synthesis, modulating nausea pathways.
Dimenhydrinate is a histamine H1 antagonist with central anticholinergic activity. It acts by blocking H1 receptors in the brain's vomiting center and inhibiting vestibular stimulation. It also has anticholinergic effects by binding to muscarinic receptors, reducing motion sickness.
10 mg doxylamine succinate + 10 mg pyridoxine hydrochloride orally once daily at bedtime, increased to twice daily (one tablet in morning and one at bedtime) and then three times daily (one tablet in morning, one in midafternoon, and one at bedtime) as needed, max 4 tablets per day.
50-100 mg orally or intramuscularly every 4-6 hours as needed; maximum 400 mg per day. For motion sickness, 50-100 mg 30 minutes before travel.
None Documented
None Documented
Clinical Note
moderateDimenhydrinate + Venlafaxine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine."
Clinical Note
moderateDimenhydrinate + Nefazodone
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone."
Clinical Note
moderateDimenhydrinate + Stiripentol
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol."
Clinical Note
moderateDoxylamine: 10-12 hours (range 6-15h) in healthy adults; prolonged in hepatic impairment or elderly. Pyridoxine: 15-20 days (as pyridoxal phosphate in tissues); elimination half-life of pyridoxine per se is 2-3 hours.
Terminal elimination half-life is 5-10 hours in adults, longer in elderly or hepatic impairment (up to 15 hours).
Renal: mostly as metabolites. Doxylamine: ~60% as unchanged drug and metabolites; pyridoxine: ~70-80% as metabolites (primarily 4-pyridoxic acid). Fecal: minimal (<10%) for both components.
Primarily renal, with 60-80% of the dose excreted unchanged in urine; minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Antiemetic
Antiemetic
Dimenhydrinate + Clomipramine
"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine."